On June 5, 2024 The University of Texas MD Anderson Cancer Center reported that patients requiring radiation therapy for head and neck cancer benefit from proton therapy based on preliminary data from a multi-institution Phase III trial led by its researchers (Press release, MD Anderson, JUN 5, 2024, View Source [SID1234644152]). The results were presented today at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting by Steven Frank, M.D., professor of Radiation Oncology and executive director of the Particle Therapy Institute at The University of Texas MD Anderson Cancer Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The trial concluded that proton therapy was effective while producing fewer side effects, emerging as the standard of care treatment that reduces malnutrition and gastrostomy-tube dependence.

"This pivotal trial provides level-one evidence supporting the use of proton therapy for head and neck cancer and demonstrates the positive impact proton therapy can have on a patient’s health during and after treatment," said Director Jennifer Maggiore, executive director of the National Association for Proton Therapy (NAPT). "This is significant because reducing side effects is valuable in supporting patient quality of life. Proton therapy can also lower payor costs and alleviate patient financial toxicity by reducing out-of-pocket spending and loss of income related to side effects."

Of an estimated 71,100 people who will be diagnosed with head and neck cancer in 2024, only 2,200 – less than 5% – are likely to be treated with proton therapy, according to NAPT member data. Lack of access to proton therapy is often due to barriers including insurance prior authorizations and denials, which can lead to harmful delays in care.

"The numbers point to a need not only for greater access, but also to the imperative for additional patient, physician and payor education regarding the value of proton therapy," said Maggiore. "NAPT will continue to advocate for more widespread adoption of proton therapy as the standard of care, while facilitating additional research that continues to prove the value of this life-saving, life-changing cancer treatment."

NAPT is an independent nonprofit organization founded in 1990 to educate and increase awareness about the clinical benefits of proton therapy. Its members include 48 of the nation’s leading cancer centers, many of which are NCI-designated comprehensive cancer centers and NCCN members.